Our top pick for
Brickell Biotech, Inc is a biotechnology business based in the US. Brickell Biotech shares (BBI) are listed on the NASDAQ and all prices are listed in US Dollars. Brickell Biotech employs 15 staff and has a trailing 12-month revenue of around USD$2.5 million.
|Latest market close||USD$0.7076|
|52-week range||USD$0.47 - USD$3.98|
|50-day moving average||USD$0.6482|
|200-day moving average||USD$0.8345|
|Wall St. target price||USD$5.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-9.546|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-33.87%|
|1 month (2020-12-17)||2.55%|
|3 months (2020-10-15)||-21.38%|
|6 months (2020-07-15)||-14.75%|
|1 year (2020-01-15)||-53.75%|
|2 years (2019-01-15)||-25.52%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-15)||98.54%|
|Revenue TTM||USD$2.5 million|
|Gross profit TTM||USD$-12,297,000|
|Return on assets TTM||-51.63%|
|Return on equity TTM||-132.17%|
|Market capitalisation||USD$42.5 million|
TTM: trailing 12 months
There are currently 1.2 million Brickell Biotech shares held short by investors – that's known as Brickell Biotech's "short interest". This figure is 112.1% up from 579,343 last month.
There are a few different ways that this level of interest in shorting Brickell Biotech shares can be evaluated.
Brickell Biotech's "short interest ratio" (SIR) is the quantity of Brickell Biotech shares currently shorted divided by the average quantity of Brickell Biotech shares traded daily (recently around 2.6 million). Brickell Biotech's SIR currently stands at 0.48. In other words for every 100,000 Brickell Biotech shares traded daily on the market, roughly 480 shares are currently held short.
However Brickell Biotech's short interest can also be evaluated against the total number of Brickell Biotech shares, or, against the total number of tradable Brickell Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Brickell Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Brickell Biotech shares in existence, roughly 20 shares are currently held short) or 0.0238% of the tradable shares (for every 100,000 tradable Brickell Biotech shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Brickell Biotech.
Find out more about how you can short Brickell Biotech stock.
We're not expecting Brickell Biotech to pay a dividend over the next 12 months.
Brickell Biotech's shares were split on a 1:7 basis on 3 September 2019. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brickell Biotech shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Brickell Biotech shares which in turn could have impacted Brickell Biotech's share price.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.